Patents Represented by Attorney Alexander Wilson
-
Patent number: 8128927Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.Type: GrantFiled: October 15, 2009Date of Patent: March 6, 2012Assignee: Eli Lilly and CompanyInventors: Julian Davies, Craig Duane Dickinson, David Matthew Marquis, Ying Tang, Peter Edward Vaillancourt
-
Patent number: 7807691Abstract: The present invention provides a compound of the Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of Formula (I).Type: GrantFiled: May 10, 2006Date of Patent: October 5, 2010Assignee: Eli Lilly and CompanyInventors: Konstantinos Gavardinas, Prabhakar Kondaji Jadhav, Douglas Richard Stack
-
Patent number: 7803814Abstract: The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).Type: GrantFiled: December 8, 2004Date of Patent: September 28, 2010Assignee: Eli Lilly and CompanyInventors: Konstantinos Gavardinas, Jonathan Edward Green, Prabhakar Kondaji Jadhav, Donald Paul Matthews
-
Patent number: 7728150Abstract: The present invention provides a compound of the formula: Formula (I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, hypertension, and atherosclerosis, comprising administering to a patient in thereof an effective amount of a compound of Formula I.Type: GrantFiled: February 18, 2005Date of Patent: June 1, 2010Assignee: Eli Lilly and CompanyInventors: Konstantinos Gavardinas, Prabhakar Kondaji Jadhav, Minmin Wang
-
Patent number: 7601738Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).Type: GrantFiled: December 14, 2005Date of Patent: October 13, 2009Assignee: Eli Lilly and CompanyInventors: Thomas John Bleisch, Jose Antonio Martinez-Perez, Paul Leslie Ornstein
-
Patent number: 7482344Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).Type: GrantFiled: December 15, 2004Date of Patent: January 27, 2009Assignee: Eli Lilly and CompanyInventors: Michael Joseph Coghlan, Prabhakar Kondaji Jadhav, James Joseph Droste, Jonathan Edward Green, Donald Paul Matthews
-
Patent number: 7411072Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.Type: GrantFiled: June 13, 2003Date of Patent: August 12, 2008Assignee: Eli Lilly and CompanyInventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
-
Patent number: 7250442Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation, particularly congestive heart failure, comprising administering to a patient in need thereof an effective amount of a compound of the formula: I or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 11, 2003Date of Patent: July 31, 2007Assignee: Eli Lilly and CompanyInventors: Matthew Lee Brown, Timothy Alan Grese, Prabhakar Kondaji Jadhav, David Andrew Neel, Mitchell Irvin Steinberg, Peter Ambrose Lander
-
Patent number: 7247644Abstract: Thus, the present invention provides compounds of formula (I) The present invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of a neurological disorder.Type: GrantFiled: April 14, 2003Date of Patent: July 24, 2007Assignee: Eli Lilly and CompanyInventor: Paul Leslie Ornstein
-
Patent number: 7205313Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).Type: GrantFiled: December 19, 2001Date of Patent: April 17, 2007Assignee: Eli Lilly and CompanyInventors: Thomas John Bleisch, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
-
Patent number: 7157582Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.Type: GrantFiled: January 11, 2005Date of Patent: January 2, 2007Assignee: Eli Lilly and CompanyInventors: Sandra Ann Filla, Paul Leslie Ornstein
-
Patent number: 6953805Abstract: The present invention provides novel compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II in combination with a suitable carrier, diluent, or excipient, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.Type: GrantFiled: December 20, 2001Date of Patent: October 11, 2005Assignee: Eli Lilly and CompanyInventors: Sandra Ann Filla, Kevin John Hudziak, Brian Michael Mathes, Paul Leslie Ornstein
-
Patent number: 6924294Abstract: The present invention provides novel compounds of Formula (I), or the pharmaceutically acceptable salts or prodrugs thereof, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.Type: GrantFiled: December 19, 2001Date of Patent: August 2, 2005Assignee: Eli Lilly and CompanyInventors: Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Ana Maria Escribano
-
Patent number: 6855725Abstract: The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.Type: GrantFiled: December 20, 2001Date of Patent: February 15, 2005Assignee: Eli Lilly and CompanyInventors: Thomas John Bleisch, Sandra Ann Filla, Paul Leslie Ornstein
-
Patent number: 6855823Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.Type: GrantFiled: April 9, 2004Date of Patent: February 15, 2005Assignee: Eli Lilly and CompanyInventors: Sandra Ann Filla, Paul Leslie Ornstein
-
Patent number: 6759418Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR4 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 rec antagonists.Type: GrantFiled: March 6, 2003Date of Patent: July 6, 2004Assignee: Eli Lilly and CompanyInventors: Sandra Ann Filla, Paul Leslie Ornstein
-
Patent number: 6579886Abstract: The present invention provides compounds of formula (I): wherein W represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; and X represents hydrogen, C1-C4 alkyl, —CH2CO2H, or CO2H; with the proviso that at least one of W or X must be other than hydrogen; or a prodrug or a pharmaceutically acceptable salt thereof; which are useful for treating migraine.Type: GrantFiled: September 3, 2002Date of Patent: June 17, 2003Assignee: Eli Lilly and CompanyInventors: Michael Gregory Bell, Michael Edward Le Tourneau, Michael John Martinelli, Mark Alan Winter
-
Patent number: 6566370Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.Type: GrantFiled: December 11, 2001Date of Patent: May 20, 2003Assignee: Eli Lilly and CompanyInventors: David Bleakman, Sandra Ann Filla, Kirk Willis Johnson, Paul Leslie Ornstein
-
Patent number: 6486175Abstract: The present invention relates to novel prodrug forms of 3S,4aR,6S,8aR-6-(((4-carboxy)phenyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid, to pharmaceutical compositions containing the prodrug forms, and to methods of using the prodrug forms.Type: GrantFiled: December 11, 2001Date of Patent: November 26, 2002Assignee: Eli Lilly and CompanyInventors: Thomas John Bleisch, Edward Louis Mattiuz, Paul Leslie Ornstein, Robert Eugene Stratford
-
Patent number: 6482824Abstract: Use of a compound of formula (I) in which, R1, R2 and R3 are independently hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, C3-C10)cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted aryl(C1-C6)alkyl, unsubstituted or substituted aryl(C2-C6)alkenyl, halo, carboxy, (C1-C6)alkoxycarbonyl or —(CH2)m—OH wherein m is 1, 2 or 3; - - - indicates a single or a double bond; X and each independently hydrogen, or X and Y together represent a bridge of the formula —CH2)m—, where n is 1 or 2; A1 and A2 are each independently an unsubstituted or substituted aryl; Z is —CO—, —SO2— or —CH2; provided that, when Z is —CO—, A1 is not 3,4,5-trimethoxyphenyl; or a pharmaceutically-acceptable salt or ester thereof, for the manufacture of a medicament for the treatment of a condition indicating the administration of a selective mGluR1 antagonist.Type: GrantFiled: July 30, 2001Date of Patent: November 19, 2002Assignee: Eli Lilly and CompanyInventors: Barry Peter Clark, John Richard Harris, Ann Elizabeth Kingston